{
    "nctId": "NCT04398914",
    "briefTitle": "Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer",
    "officialTitle": "A Randomised, Multicenter, Open-label, Phase II Study Evaluating Pyrotinib Plus Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in Early Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2 - Positive Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer Invasive",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 216,
    "primaryOutcomeMeasure": "Percentage of Participants With Total Pathologic Complete Response (tpCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* With signed consent\n* Histologically confirmed invasive breast carcinoma with a primary tumor size of no less than (\u2265) 2 centimeters (cm) by standard local assessment technique\n* Breast cancer stage at presentation: stage II-III\n* HER2-positive breast cancer defined as 3+ score by immunohistochemistry in \\> 10 percent (%) of immunoreactive cells or HER2 gene amplification by in situ hybridization\n* Known hormone receptor status (estrogen receptor and/or progesterone receptor)\n* Eastern Cooperative Oncology Group Performance Status equal to or less than (\\<=) 1\n* Baseline left ventricular ejection fracture \\>= 50% measured by echocardiography\n* Willing to use highly effective form of nonhormonal contraception while on study and for 7 months after end of study treatment for female with fertility or male\n* Willing to obey the study protocol\n\nExclusion Criteria:\n\n* Stage IV disease\n* Previous anti-cancer therapy or radiotherapy for any malignancy\n* History of other malignancy within 5 years prior to screening, except for appropriately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, ,Stage I uterine cancer or thyroid papillary microcarcinoma\n* Concurrent anti-cancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy\n* Major surgical procedure unrelated to breast cancer within 4 weeks prior to randomization or from which the participant has not fully recovered\n* Serious cardiac illness or medical condition\n* Other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness\n* Any abnormalities in liver, kidney or hematologic function laboratory tests immediately prior to randomization\n* Sensitivity to any of the study medications, any of the ingredients or excipients of these medications, or benzyl alcohol\n* Not able to swallow the drug\n* Pregnant or lactating\n* Positive serum or urine pregnancy test or above mentioned tests cannot be achieved for women with fertility",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}